Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk.

Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression.

CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression.

Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer.

CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients.

CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring.

CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies.

Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types.

Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment.

Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance.

HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions.

CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions.

A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk.

A trial found CTCs in 60% of early-stage breast cancer patients, notably all HER2-positive cases, linking them to tumor grade. Send the next!

CTC analysis in 134 patients successfully detected PD-L1, HER2, and EGFR, proving its value as a real-time guide for targeted therapies.

Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis.

Study of 127 patients shows CTCs are a dynamic biomarker for monitoring disease progression and therapy response in advanced epithelial cancers.

An XGBoost ML model using CTCs and clinical data achieved 84% accuracy in predicting the need for adjuvant therapy in 380 HNSCC patients.

A 3D-printed G-EpCAM device successfully captured over 85% of CTCs with minimal hemolysis, offering a new way to stem metastatic progression.

A phase II trial shows EMF triplet therapy is a safe, effective option for HNSCC, with CTCs serving as a promising biomarker for therapy response.